See more : Ksolves India Limited (KSOLVES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Chemomab Therapeutics Ltd. (CMMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chemomab Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Huarong Asset Management Co., Ltd. (2799.HK) Income Statement Analysis – Financial Results
- SOFT99corporation (4464.T) Income Statement Analysis – Financial Results
- China Quanjude(Group) Co.,Ltd. (002186.SZ) Income Statement Analysis – Financial Results
- G-Resources Group Limited (GGPXF) Income Statement Analysis – Financial Results
- MotorCycle Holdings Limited (MTO.AX) Income Statement Analysis – Financial Results
Chemomab Therapeutics Ltd. (CMMB)
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 66.83K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| Gross Profit | -66.83K | -57.77K | -34.02K | -80.00K | -281.91K | -66.00K | -51.00K | -40.64K | -26.25K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 16.98M | 6.33M | 4.68M | 13.35M | 7.51M | 6.23M | 2.34M | 5.96M | 15.72M |
| General & Administrative | 7.08M | 11.56M | 6.03M | 1.29M | 960.00K | 374.00K | 0.00 | 0.00 | 0.00 | 5.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 5.96M | 5.08M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.56M | 6.03M | 1.29M | 5.98M | 5.46M | 3.11M | 2.25M | 1.14M | 5.65M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 749.00K | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.33M | 12.97M | 9.34M | 4.59M | 7.11M | 21.37M |
| Cost & Expenses | 25.46M | 28.53M | 12.37M | 5.97M | 19.61M | 13.04M | 9.39M | 4.63M | 7.13M | 21.37M |
| Interest Income | 1.23M | 351.62K | 65.00 | 20.00K | 393.00K | 0.00 | 1.00K | 521.00 | 1.03K | 0.00 |
| Interest Expense | 0.00 | 353.00K | 111.08K | 6.00K | 9.00K | 0.00 | 5.00K | 0.00 | 14.16K | 0.00 |
| Depreciation & Amortization | 67.00K | 57.77K | 34.02K | 80.00K | 281.91K | 66.00K | 51.00K | 40.64K | 26.25K | 0.00 |
| EBITDA | -25.39M | -28.48M | -12.33M | -5.95M | -26.92M | -13.36M | -9.50M | -4.57M | -7.46M | 24.18M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.46M | -28.53M | -12.40M | -5.97M | -19.61M | -13.04M | -9.39M | -4.63M | -7.13M | 24.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.24M | 353.00K | -111.00K | 21.00K | -7.60M | -455.52K | -164.63K | 20.69K | -367.79K | 29.24M |
| Income Before Tax | -24.22M | -28.18M | -12.48M | -5.95M | -27.21M | -13.49M | -9.48M | -4.60M | -7.50M | 24.18M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -534.00K | 77.00K | -21.00K | 1.00 | 306.00K | 323.00K | 136.24K | -3.00 | 0.00 |
| Net Income | -24.22M | -27.65M | -12.56M | -5.93M | -27.21M | -13.80M | -9.81M | -4.73M | -7.50M | 24.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| EPS Diluted | -2.06 | -2.43 | -1.21 | -3.20 | -15.80 | -21.84 | -217.31 | -17.42 | -32.94 | 0.00 |
| Weighted Avg Shares Out | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
| Weighted Avg Shares Out (Dil) | 11.75M | 11.38M | 10.37M | 1.85M | 1.72M | 631.70K | 45.13K | 271.67K | 227.69K | 50.11B |
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
─Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 ─ ─Cash Runway Extended through End of First Quarter 2025 as a Result of Early...
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor will deliver a corporate presentation...
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— — New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for...
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting...
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr....
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab's CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— —CM-101 Phase...
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
—Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial— —CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in PSC, Which Often Results in Liver...
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB), indicating that the stock has found support.
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Activates Endothelial Cells in Specific Ways that Result in SSc-Associated Fibrosis -- TEL AVIV,...
Source: https://incomestatements.info
Category: Stock Reports